Immunogen Inc (IMGN)

2.00
0.01 0.25
NASDAQ : Health Care
Prev Close 2.00
Open 2.05
Day Low/High 1.91 / 2.05
52 Wk Low/High 2.68 / 18.78
Volume 787.92K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 87.30M
Market Cap 164.13M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ImmunoGen Announces Preclinical Data Presentations For Two ADCs With Novel IGN Payloads At Upcoming 58th ASH Annual Meeting

ImmunoGen Announces Preclinical Data Presentations For Two ADCs With Novel IGN Payloads At Upcoming 58th ASH Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company's novel IGN ADCs, IMGN632 and...

ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights

ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reported financial results and reviewed business highlights for the three-month...

ImmunoGen, Inc. Announces Conference Call To Discuss Its Financial Results For Quarter Ended September 30

ImmunoGen, Inc. Announces Conference Call To Discuss Its Financial Results For Quarter Ended September 30

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Completes Strategic Review To Strengthen The Organization And Drive Long-Term Growth

ImmunoGen Completes Strategic Review To Strengthen The Organization And Drive Long-Term Growth

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of a strategic review of its operations.

IMGN April 2017 Options Begin Trading

IMGN April 2017 Options Begin Trading

Investors in ImmunoGen, Inc. saw new options begin trading today, for the April 2017 expiration.

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.

ImmunoGen Announces Departure Of Chief Development Officer

ImmunoGen Announces Departure Of Chief Development Officer

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief...

Strong On High Relative Volume: Immunogen (IMGN)

Strong On High Relative Volume: Immunogen (IMGN)

Trade-Ideas LLC identified Immunogen (IMGN) as a strong on high relative volume candidate

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

ImmunoGen Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Provides Quarterly Business Update

ImmunoGen Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Provides Quarterly Business Update

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today provided an update on the Company's progress and reported financial results for...

5 Hated Earnings Stocks You Should Love

5 Hated Earnings Stocks You Should Love

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade five stocks trading for less than $10 a share.

ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2016 Financial Results

ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2016 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics, today announced that the Company will host a conference call at 8:00 a.

First Week of August 19th Options Trading For ImmunoGen (IMGN)

First Week of August 19th Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options become available this week, for the August 19th expiration.

ImmunoGen Announces Pricing Of $100 Million Offering Of 4.50% Convertible Senior Notes Due 2021

ImmunoGen Announces Pricing Of $100 Million Offering Of 4.50% Convertible Senior Notes Due 2021

ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.

ImmunoGen Announces Proposed $100 Million Offering Of Convertible Senior Notes Due 2021

ImmunoGen Announces Proposed $100 Million Offering Of Convertible Senior Notes Due 2021

ImmunoGen, Inc. (NASDAQ: IMGN) today announced its intention to offer and sell to the initial purchasers, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2021...

ImmunoGen Becomes Oversold (IMGN)

ImmunoGen Becomes Oversold (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Immunogen (IMGN) Weak On High Volume

Immunogen (IMGN) Weak On High Volume

Trade-Ideas LLC identified Immunogen (IMGN) as a weak on high relative volume candidate

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

ImmunoGen Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In FRa-Positive Ovarian Cancer

ImmunoGen Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In FRa-Positive Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) cancer therapeutics, today reported the clinical data from a 46-patient Phase 1 cohort evaluating the...

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company...

Relative Strength Alert For ImmunoGen

Relative Strength Alert For ImmunoGen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Immunogen (IMGN): Today's Weak On High Volume Stock

Immunogen (IMGN): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Immunogen (IMGN) as a weak on high relative volume candidate

ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary ADC technology, today reported financial results for the three-month period ended March 31, 2016 - the...

ImmunoGen Appoints Mark J. Enyedy As President And Chief Executive Officer

ImmunoGen Appoints Mark J. Enyedy As President And Chief Executive Officer

ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J.

ImmunoGen Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia

ImmunoGen Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its extensive ADC technology portfolio, today announced the start of clinical testing of the Company's IMGN779...

ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at...

Daniel Junius To Retire As President And CEO Of ImmunoGen, Inc.

Daniel Junius To Retire As President And CEO Of ImmunoGen, Inc.

ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to...